In a remarkable breakthrough for those battling motor neurone disease, a promising new drug has emerged, offering hope for an extended lifespan and improved quality of life. This development centers around a medication that has shown potential in slowing the progression of amyotrophic lateral sclerosis (ALS), the most prevalent form of the disease.

ALS is a debilitating condition characterized by muscle wasting that severely impacts the nervous system. The disease is known for its relentless progression, gradually robbing patients of their ability to move, speak, swallow, and even eat, all while remaining without a cure.

However, scientific advancements have introduced pridopidine, a twice-daily pill that researchers believe may decelerate the disease’s advancement. This medication not only holds promise in preserving motor functions but also in extending the survival of those afflicted.

The underlying mechanism of pridopidine involves the sigma-1 receptor (SIR), which has been identified as a key player in activating numerous neuroprotective pathways. These pathways are crucial in the context of neurodegenerative diseases like ALS and Huntington’s Disease.

Clinical trials thus far have underscored the drug’s safety and effectiveness, with data from over 1,600 patients supporting these findings. Some participants have benefitted from active treatment for as long as seven years, marking a significant step forward in the fight against this challenging illness.

So far, clinical studies have demonstrated its safety and efficacy with data from more than 1,600 patients, some of which have received active treatment for seven years. 

Yesterday, the manufacturers of the drug, Prilenia Therapeutics and Ferrer, announced their first enrollment in the pivotal study in patients with rapidly progressive ALS. 

Whilst it’s currently not approved by any regulatory authority, researchers believe the global study, which will involve more than 500 participants, could pave the way for therapeutic treatments that slow down the progression of the disease. 

Dr Sabrina Paganoni, co-director of the Mass General Brigham neurological clinical research institute, said: ‘Enrolling the first participant in this confirmatory study is a milestone in our search for potential new therapeutic options that may help to preserve function, maintain speech and prolong survival – key aims of early ALS therapy.’ 

MND charities have welcomed the next stage of the trial, highlighting the need for early diagnosis and treatment. 

Kuldip Dave, Senior Vice President of Research at the ALS Association said: ‘The ALS community urgently needs new treatment options that can delay the disease’s relentless progression, and awaits the outcome of this study. 

‘The earlier we can diagnose and treat ALS,  the greater the potential to preserve function and maintain quality of life for longer, which are key to making ALS livable until we can cure it.’ 

The PREVAiLS study is set to take place in up to 60 leading ALS treatment centers across 13 countries including the US, EU and the UK. 

The 48-week placebo study seeks to enroll patients with definite or probable ALS who are within 18 months of their symptoms first appearing. 

ALS claimed the life of Grey’s Anatomy star Eric Danes at just 53-years-old earlier this year and the acclaimed scientist Stephen Hawking famously suffered from it. 

Danes, who played the role of Dr Mark Sloan, announced he had been diagnosed with ALS less than a year before he passed away. 

Grey’s Anatomy and Euphoria fans reacted with shock and sadness at the news that star Eric Dane has passed away with a form of deadly motor neurone disease

The TV hunk is best known being Dr Mark Sloan, above with Dr Derek Shepherd, played by Patrick Dempsey, on Grey’s Anatomy from 2006

It is not fully understood why MND occurs and there are currently no treatments to halt its cruel march – instead doctors focus on alleviating the worst of the symptoms. 

Around 5,000 adults in the UK have the condition and there is a one in 300 risk of developing it over the course of a lifetime. 

The disease causes muscle weakness that gets worse over a few months or years, 

Symptoms typically first include stiff or weak hands, weak less and feet which may cause someone to trip over a lot, and twitches spasms or muscle cramps. 

As MND gets worse, a sufferer may experience problems breathing, swallowing and speaking. Eventually they will no longer be able to walk or move.  

Life expectancy for about half of those with the condition is between just two and give years from the onset of symptoms. But these can worsen rapidly.

Some people may live for up to 10 years, and, in rarer circumstances, even longer.